Dr Reddy’s Lab shares hit new 52-wk high on patent suit settlement with Celgene; more than doubles in 6 months

Dr. Reddy's Laboratories shares have rallied 15.55 per cent, in comparison, S&P BSE Sensex gained just 1.14 per cent. The company announced the settlement of US Revlimid® (lenalidomide) capsules patent litigation with Celgene.